Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Part of paid clinical trials in Tucson, Arizona.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00871923
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Tarceva (Erlotinib hydrochloride) — DRUG
    150 mg by mouth every day beginning Day 1.
  • Radiation Therapy — RADIATION
    Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.

Study Details

The goal of this clinical research study is to learn whether Tarceva (erlotinib hydrochloride), when given in addition to whole brain radiation therapy, is better to treat brain metastases in patients with Non-Small Cell Lung Cancer (NSCLC).

Key Dates

First listed
Mar 30, 2009
Start date
Mar 26, 2009
Status verified
Sep 2021
Primary completion
Dec 4, 2019
Completion
Dec 4, 2019

Study Design

Enrollment
44 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tarceva + RT
    Tarceva (Erlotinib hydrochloride) + Radiation Therapy. Tarceva 150 mg by mouth every day beginning Day 1. Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.

Primary Outcome Measure

Median Survival [ Time Frame: End-of-study visit 1 month after radiation therapy completed, and follow-up visits every 3 months, assessed up to 2 years. ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of ArizonaTucsonArizona85721-
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Tucson, AZ

By condition
Brain cancerLung cancer
By specialty
OncologyNeuro-oncologyLung oncologyLung disease
By research site
University of Arizona· Tucson, AZUniversity of Texas MD Anderson Cancer Center· Houston, TX

Related Studies